Evidence map›Paper›PMID 15489957›Full record

ArticleThe Journal of clinical investigation2004

Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis.

Jörn Karhausen, Glenn T Furuta, John E Tomaszewski, Randall S Johnson, Sean P Colgan, Volker H Haase

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 374 papers.

0numbers the graph read from it
0cells of the map it votes in
374citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

374 citing papers in PubMed, 567 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

314 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Jörn KarhausenCenter for Experimental Therapeutics and Reperfusion Injury, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
Glenn T Furuta
John E Tomaszewski
Randall S Johnson
Sean P Colgan
Volker H Haase
Brigham and Women's Hospital · USUniversity of Pennsylvania · USUniversity of California San Diego · US

Funding

Novel anti-inflamatory lipid mediatorsP01DE013499 · NIDCR · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SERHAN, CHARLES NICHOLAS · 2000 to 2004
$5.3M
ROLE OF EPITHELIA IN ISCHEMIA/REPERFUSION INJURYR01DK050189 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI COLGAN, SEAN P · 2000 to 2024
$5.0M
Hypoxia, HIF, and Mucosal InflammationR37DK050189 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI COLGAN, SEAN P · 2010 to 2019
$4.1M
Neutrophils and Vascular Endothelial PermeabilityR01HL060569 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI COLGAN, SEAN P · 1999 to 2013
$3.5M
VHL FUNCTION BY CONDITIONAL GENE TARGETINGK08DK002668 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI HAASE, VOLKER H. · 1999 to 2003
$502k
Functional Studies of VHL by Conditional Gene TargetingR03DK062060 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI HAASE, VOLKER H. · 2002 to 2003
$159k
EPITHELIA AND ISCHEMIA/REPERFUSION INJURYR29DK050189 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI COLGAN, SEAN P · 1995 to 1999
–
NHLBI NIH HHS HL60569NHLBI NIH HHS R01 HL060569NIDCR NIH HHS P01 DE013499NIDCR NIH HHS P01 DE13499NIDDK NIH HHS DK02668NIDDK NIH HHS DK062060NIDDK NIH HHS DK50189NIDDK NIH HHS K08 DK002668NIDDK NIH HHS R01 DK050189NIDDK NIH HHS R03 DK062060NIDDK NIH HHS R29 DK050189NIDDK NIH HHS R37 DK050189
6 · The paper itself

Abstract

Mucosal epithelial cells are uniquely equipped to maintain barrier function even under adverse conditions. Previous studies have implicated hypoxia in mucosal tissue damage resulting from both acute and chronic inflammation. Given the importance of the transcriptional regulator hypoxia-inducible factor-1 (HIF-1) for adaptive hypoxia responses, we hypothesized that HIF-1 may serve as a barrier-protective element during mucosal inflammation. Initial studies of hapten-based murine colitis revealed extensive mucosal hypoxia and concomitant HIF-1 activation during colitis. To study this in more detail, we generated 2 mouse lines with intestinal epithelium-targeted expression of either mutant Hif1a (inability to form HIF-1) or mutant von Hippel-Lindau gene (Vhlh; constitutively active HIF-1). Studies of colitis in these mice revealed that decreased HIF-1 expression correlated with more severe clinical symptoms (mortality, weight loss, colon length), while increased HIF levels were protective in these parameters. Furthermore, colons with constitutive activation of HIF displayed increased expression levels of HIF-1-regulated barrier-protective genes (multidrug resistance gene-1, intestinal trefoil factor, CD73), resulting in attenuated loss of barrier during colitis in vivo. Taken together, these studies provide insight into tissue microenvironmental changes during model inflammatory bowel disease and identify HIF-1 as a critical factor for barrier protection during mucosal insult.

Indexed as

AnimalsCarrier ProteinsCell HypoxiaColitisDNA-Binding ProteinsGene DeletionGene Expression RegulationGenes, ReporterHumansHypoxia-Inducible Factor 1Hypoxia-Inducible Factor 1, alpha SubunitIntestinal MucosaMiceMice, Inbred StrainsMice, TransgenicNuclear ProteinsCarrier ProteinsDNA-Binding ProteinsHIF1A protein, humanHif1a protein, mouseHypoxia-Inducible Factor 1Hypoxia-Inducible Factor 1, alpha SubunitNuclear ProteinsTranscription Factors

Identifiers

PMID15489957
PMCPMC522241
OpenAlexW1982920345

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.